SSX2B is altered in 3.23% of synovial sarcoma patients [3].

SSX2B is an inclusion criterion in 2 clinical trials for synovial sarcoma, of which 1 is open and 1 is closed. Of the trials that contain SSX2B status and synovial sarcoma as inclusion criteria, 2 are phase 1 (1 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is altered in 0.12% of breast carcinoma patients [3].

SSX2B is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is altered in 0.05% of malignant solid tumor patients [3].

SSX2B is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SSX2B is altered in 0.26% of soft tissue sarcoma patients [3].

SSX2B is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].